Stellar Pharmaceutical Inc. Form 8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
     

FORM 8-K
     

Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 
 
  March 31, 2006
  
 
 Date of Report (date of earliest event reported):
  
 
 
Stellar Pharmaceuticals Inc.
 
 
 (Exact Name of Registrant as Specified in Its Charter)
  

 Ontario
000-31198
N/A
 (State or other juristiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
     
 
544 Egerton Street, London, Ontario, Canada
N5W 3Z8
 
(Address of Principal Executive Offices)
(Zip Code)
 
 
(519) - 434-1540
  
 
(Registrant’s Telephone Number, Including Area Code)
  
 
 
 N/A
  
 
 (Former Name or Former Address, if Changed Since Last Report)
  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

TABLE OF CONTENTS
 
Item 2.02 Results of Operations and Financial Condition
Item 9.01 Financial Statements of Exhibits and Exhibits
SIGNATURES
Press Release
 
Item 2.02 Results of Operations and Financial Condition 

On March 31, 2006, Stellar Pharmaceuticals Inc. (the "Company") issued a press release with its financial results for the year ended December 31, 2005. The full text of the press release issued in connection with the announcement is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits
 
99.1 Press Release, dated March 31, 2006, issued by the Company.
 
The information contained in this Current Report under Item 2.02, including the exhibit referenced in Item 9.01, is being “furnished” pursuant to “Item 2.02 Results of Operations and Financial Condition” of Form 8-K and, as such, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in Item 2.02 of this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
 
 
 
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
STELLAR PHARMACEUTICALS INC.
 
 
 
 
Date: March 31, 2006
By:
/s/ Janice Clarke
 
 
 
Janice Clarke
   
Chief Financial Officer